WHO invites laboratories to participate in WHO External Quality Assurance Assessment Scheme
Phase 9 studies - Last seats available!
15 September 2018 - Quality control (QC) testing is complex, and errors are costly and may jeopardize patient safety. Given these high stakes, trust in a QC laboratory’s capabilities is essential for all stakeholders who request its services. The WHO External Quality Assurance Assessment Scheme (EQAAS) is a proficiency test scheme organized with a view to evaluating the technical performance of pharmaceutical quality control laboratories designated by WHO. EQAAS gives each participating quality control laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure. Regular studies are carried out on widely used methods of analysis in the physicochemical field including methods used in pharmaceutical technology such as dissolution testing. WHO at present offers the only global independent scheme and, laboratories from all WHO’s six regions have participated in the studies.
EQAAS was established by WHO in 2000 at the request of the Global Fund as a mechanism to maximize health benefits achieved on grant investments in pharmaceuticals and laboratory supplies. The Scheme has proven to be a major asset to WHO Member States. Participation in such studies is mandatory according to WHO’s good practices for pharmaceutical quality control laboratories and for ISO 17025 accreditation.
For more information and expression of interest to participate, please contact WHO at the following email: EQAAS@who.int
For further information on WHO’s good practices for pharmaceutical quality control laboratories:
WHO good practices for pharmaceutical quality control laboratories